Drug Profile


Alternative Names: hGH-rPEG - Versartis; hGH-XTEN; Human growth hormone-XTEN - Amunix; Recombinant human growth hormone long-acting - Versartis; Somatropin long-acting - Versartis; VRS-317

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Versartis
  • Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 03 Apr 2017 Efficacy and adverse event data from the phase I/II VERTICAL trial and the phase II/III VISTA trial in Somatotropin deficiency presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 21 Feb 2017 Versartis intends to submit BLA to the US FDA in 2018
  • 30 Jan 2017 Versartis plans a phase III trial for Somatotropin deficiency (In adults)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top